Indicated for: allergic rhinitis; urticaria
Route of administration: inhalation
Substance: chlorpheniramine maleate + betamethasone (antiallergic agent + glucocorticoid)
ATC: R01ADN1 (Respiratory system | Decongestants and other nasal preparations for topical use | Corticosteroids)
This combination of chlorpheniramine maleate and betamethasone is used for the treatment of allergic and inflammatory conditions such as allergic rhinitis, urticaria, atopic dermatitis, or other severe allergic reactions. Chlorpheniramine reduces allergic symptoms, while betamethasone combats inflammation and excessive immune responses.
It is taken orally as directed by a doctor, usually in tablet form. It is intended for short-term use during acute episodes to minimize the risk of side effects associated with corticosteroids.
Common side effects include drowsiness, dizziness, dry mouth (due to chlorpheniramine), increased appetite, fluid retention, or hyperglycemia (due to betamethasone).
This combination is contraindicated in patients with untreated systemic infections, glaucoma, uncontrolled diabetes, or severe hypertension. It should be used with caution in children, as corticosteroids may affect growth.
Patients should strictly follow their doctor’s instructions and avoid alcohol consumption, which may enhance the sedative effects of chlorpheniramine.